Pulmonary Hypertension
Conditions
Brief summary
The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and PH phenotype.
Interventions
DRUGVasodilator testing (Inhaled Nitric Oxide)
Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
DRUGVasodilator testing (Inhaled Epoprostenol)
Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
Sponsors
Brigham and Women's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* mPAP ≥ 21mmHg, PAWP ≤ 25mmHg, and PVR ≥3 WU * Classified as WHO group I-III pulmonary hypertension
Exclusion criteria
* WHO group IV and V pulmonary hypertension * Patients who are on baseline pulmonary vasodilator medications * Severe aortic or mitral valve disease * Patients who are pregnant * Left ventricular ejection fraction of \<35% * Patients who are hospitalized as inpatients at the time of RHC * Patients with systolic blood pressure \<90mmHg or mean arterial pressure of \< 60mmHg
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in mean pulmonary artery pressure | Pre-pulmonary vasodilator testing measurements (baseline) will be compared to post-pulmonary vasodilator testing measurements during diagnostic right heart catheterization. | The primary outcome will be change in mean pulmonary artery pressure (mmHg) from baseline to after 5-minutes of inhaled vasodilator. |
Countries
United States
Outcome results
None listed